Dianthus Therapeutics | MGTA - Koszty Sprzedaży I Administracji





Koszty Sprzedaży I Administracji Zmiana Data
Akebia Therapeutics USD 23.53M 3.19M 2025-12
Alaunos Therapeutics USD 447K 138K 2026-03
Avita Medical AUD 19.03M 1.95M 2025-12
Celltrion KRW 9.32B 3.39B 2026-03
Cspc Pharmaceutical CNY 1.87B 95.62M 2025-12
Deva Holding AS TRY 462.26M 48.18M 2023-09
Dianthus Therapeutics USD 12.47M 5.89M 2026-03
Divis Laboratories Ltd INR 3.4B 10M 2025-06
IQVIA Holdings USD 574M 72M 2026-06
Kangmei Pharma CNY 237.06M 37.35M 2026-03
Knight Therapeutics CAD 35.45M 4.43M 2025-12
Laboratorios Farma EUR 35.32M 2.75M 2025-06
Malin Corporation EUR 1.1M 400K 2024-12
Medical Developments International AUD 2.84M 4.19M 2025-12
Moderna USD 216M 43M 2026-06
Neuren Pharmaceuticals AUD 3.74M 2.5M 2025-12
Organigram Holdings CAD 22.01M 14.28M 2026-03
Organon & Co USD 434M 10M 2026-06
Ovoca Bio EUR 617K 15K 2025-12
Pharma Mar EUR 17.12M 1.82M 2026-06
Qiagen NV USD 142.33M 60K 2026-06
Revvity USD 278.58M 24.69M 2026-06
Sartorius EUR 221.3M 0 2026-06
Sino Biopharmaceutical CNY 7.54B 2.23B 2025-06
Tectonic Therapeutic USD 6.43M 2.99M 2026-03
Tilray USD 24.85M 1.7M 2025-09
Viatris USD 1.13B 205.7M 2026-06
Xeris Pharmaceuticals USD 53.14M 10.51M 2026-03
Zealand Pharma A/S 104M 12.19M 2026-03
Zz Pientze Pharmaceu CNY 223.14M 8.82M 2026-06